Literature DB >> 7871742

Identification of residues in the N-terminal acidic domain of HIV-1 Vpr essential for virion incorporation.

S Mahalingam1, S A Khan, M A Jabbar, C E Monken, R G Collman, A Srinivasan.   

Abstract

Vpr is one of the auxiliary proteins encoded by the HIV-1 genome and is selectively incorporated into the virus particle. It has been shown that Vpr incorporation in the virus particle requires only the core protein Gag. In an effort to identify the domains of Vpr which are essential for incorporation into the HIV-1 virion, site-specific mutagenesis of vpr was carried out. Mutation of the highly conserved acidic residues in the N-terminal domain (amino acid positions 17-34) eliminated virion incorporation. These mutations disrupt a predicted amphipathic alpha-helical structure that is highly conserved among Vpr sequences. In contrast, alterations of the conserved cysteine (Cys76), basic domain (Arg87 and Lys95), and other residues (Gln65) did not impair the incorporation of Vpr into virus-like particles directed by HIV-1 Gag. The results presented here suggest that protein-protein interactions mediated through the putative helical domain of Vpr may participate in its incorporation into the virus particle.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7871742     DOI: 10.1006/viro.1995.1081

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  35 in total

1.  The C-terminal proline-rich tail of human immunodeficiency virus type 2 Vpx is necessary for nuclear localization of the viral preintegration complex in nondividing cells.

Authors:  H A Pancio; N Vander Heyden; L Ratner
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  The amino-terminal region of Vpr from human immunodeficiency virus type 1 forms ion channels and kills neurons.

Authors:  S C Piller; G D Ewart; D A Jans; P W Gage; G B Cox
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr.

Authors:  S P Singh; B Tomkowicz; D Lai; M Cartas; S Mahalingam; V S Kalyanaraman; R Murali; A Srinivasan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Integrase mediates nuclear localization of Ty3.

Authors:  S S Lin; M H Nymark-McMahon; L Yieh; S B Sandmeyer
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

5.  Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation.

Authors:  S A Stewart; B Poon; J Y Song; I S Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  Molecular Mechanisms of Neurodegenerative Diseases Induced by Human Retroviruses: A Review.

Authors:  Bryan P Irish; Zafar K Khan; Pooja Jain; Michael R Nonnemacher; Vanessa Pirrone; Saifur Rahman; Nirmala Rajagopalan; Joyce B Suchitra; Kate Mostoller; Brian Wigdahl
Journal:  Am J Infect Dis       Date:  2009-07-01

7.  Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication.

Authors:  D Serio; T A Rizvi; M Cartas; V S Kalyanaraman; I T Weber; H Koprowski; A Srinivasan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

8.  The putative alpha helix 2 of human immunodeficiency virus type 1 Vpr contains a determinant which is responsible for the nuclear translocation of proviral DNA in growth-arrested cells.

Authors:  Z Nie; D Bergeron; R A Subbramanian; X J Yao; F Checroune; N Rougeau; E A Cohen
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

9.  Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr.

Authors:  S Mahalingam; V Ayyavoo; M Patel; T Kieber-Emmons; D B Weiner
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

10.  A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.

Authors:  Y L Lu; R P Bennett; J W Wills; R Gorelick; L Ratner
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.